Ph2 Study of Zanidatamab with Previously Treated Solid Tumors (DiscovHER-206)
Phase II Clinical Trial
A Phase 2 open-label multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)